Compare BLNK & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | TTRX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2M | 116.0M |
| IPO Year | N/A | N/A |
| Metric | BLNK | TTRX |
|---|---|---|
| Price | $0.70 | $3.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $2.13 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.4M | 41.7K |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,631,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $2.57 |
| 52 Week High | $2.65 | $26.50 |
| Indicator | BLNK | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 41.50 |
| Support Level | $0.64 | $3.55 |
| Resistance Level | $0.72 | $5.02 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 21.10 | 18.36 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.